Novo Nordisk is positioning itself as a long‑term leader across multiple obesity segments rather than relying on a single ...

In the latest fracas over the burgeoning market for weight loss drugs, a compounding pharmacy has filed a lawsuit accusing ...

AbbVie CEO said that the company is now looking at candidates that provide sustained weight loss. ・The obesity drug market is ...

Delaware Attorney General Kathy Jennings is suing several drug manufacturers and pharmacy benefit managers for reported ...

Drugmaker CEOs see sales online channels as a budding opportunity, while some biotech investors told BioPharma Dive to expect ...

MoneyShow presents top investment ideas for 2026 from leading advisors. Part 4 includes Eli Lilly, Enterprise Products ...

Pharmaceutical companies are paying thousands of Indiana doctors to talk about GLP-1 drugs, a WRTV Investigation has ...

The rising popularity of weight loss drugs is a key reason healthcare company Eli Lilly (NYSE: LLY) has been soaring in value ...

Speaking at the J.P. Morgan conference, CEO David Ricks said he anticipates a “rapid review” for orforglipron that's ...

Eli Lilly and Nvidia are putting up to $1 billion on the table to see whether generative AI can compress the decade-long slog ...

The FDA is requesting that manufacturers of three GLP-1 receptor agonists remove information on risk for suicidal ideation ...

The new drugs could become the way forward for medicated weight loss as clinical trials reveal optimistic results ...